Form 4: SERA CEO Lindgardt Receives Significant Equity Grants

SERA Prognostics CEO Zhenya Lindgardt was granted 154,440 restricted stock units and 239,442 stock options, aligning her interests with shareholders.

Summary

• Zhenya Lindgardt, Chief Executive Officer and Director of SERA Prognostics, Inc., acquired 154,440 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs were granted at a price of $0 and bring her total direct beneficial ownership of Class A Common Stock to 892,754 shares.
• The RSUs vest over four years, with 1/16 of the original grant amount vesting in quarterly installments following the vesting commencement date of March 10, 2026, subject to continued service.
• Lindgardt also acquired 239,442 stock options with an exercise price of $1.99 per share.
• These stock options were granted at a price of $0, become exercisable starting March 12, 2026, and have an expiration date of March 12, 2036.
• The stock options vest over four years, with 1/48 of the original grant amount vesting in monthly installments following the vesting commencement date of March 10, 2026, subject to continued service.
• Following these transactions, Lindgardt directly beneficially owns 239,442 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align the CEO's interests with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of 154,440 Restricted Stock Units (RSUs) and 239,442 stock options to the CEO aligns management's long-term interests with those of shareholders.
• Equity-based compensation incentivizes the CEO to drive company performance and increase shareholder value over the multi-year vesting periods.

Industry Context

StockSavvy.ai notes that equity grants to executive leadership, such as those received by SERA Prognostics' CEO, are a common practice across the biotechnology and diagnostics industry. These grants are designed to align executive incentives with long-term shareholder value creation, particularly in growth-oriented companies where future performance is key.

Comparison to Industry Standards

• The structure of these equity grants, with multi-year vesting schedules (four years for both RSUs and options), is consistent with typical executive compensation packages in the U.S. biotech sector, aiming for long-term retention and performance alignment.
• The grant of both RSUs and stock options is a common dual approach, providing both a direct equity stake (RSUs) and performance-based upside potential (options), similar to practices observed at comparable early-stage diagnostic companies like Natera (NTRA) or Veracyte (VCYT) in their growth phases.

Stakeholder Impact

• Shareholders: Potential for increased alignment of CEO's interests with shareholder value creation due to equity-based compensation.
• Employees: No direct impact mentioned, but a strong leadership team incentivized by equity can positively influence overall company performance and employee morale.

Next Steps

• Continued vesting of 154,440 Restricted Stock Units over four years, with quarterly installments, subject to continued service.
• Continued vesting of 239,442 Stock Options over four years, with monthly installments, subject to continued service.

Key Dates

Keywords

SERA Prognostics, SERA, Zhenya Lindgardt, CEO, Director, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Beneficial Ownership